Article Text

Download PDFPDF
Usage of unpublished paediatric data
  1. Agnès Saint-Raymond1,
  2. Benjamin Pelle1,
  3. Cosimo Zaccaria1,
  4. Matthias Sennwitz1,
  5. Sarah Branch2
  1. 1European Medicines Agency (EMA), London, UK
  2. 2Medicines and Healthcare Products Regulatory Agency, London, UK
  1. Correspondence to Dr Agnès Saint-Raymond, European Medicines Agency (EMA), 30 Churchill Place, Canary Wharf, London E14 5EU, UK; agnes.saint-raymond{at}


The European Paediatric Regulation (EC No 1901/2006) has three main objectives: increasing the number of appropriate medicines for children, increasing information on these medicines and stimulating high-quality ethical research with children. To contribute to the information, pharmaceutical companies were required under article 45 of the Regulation to submit existing paediatric studies to regulatory authorities for review and update of the product information. Nearly, 19 000 study reports have been identified for a thousand active substances. The data are being assessed by member states' competent authorities in collaboration with European Medicines Agency (EMA). After 7 years, 262 active substances have been assessed, all of the 62 centrally approved and nearly 200 nationally approved medicines. The review so far has led to 16 new paediatric indications, of importance in addressing previously unmet needs, in particular, in younger age groups. The information is being made publicly available in an EMA database accessible directly or through the public face of the European Clinical Trials Register. This will increase awareness of existing data that are useful to researchers and other healthcare professionals, and contribute to avoiding unnecessary duplication of paediatric trials.

  • Evidence Based Medicine
  • Neonatology
  • Therapeutics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.